|
January 2003 (v03-n01) |
|
- Main Story - pgs. 1-16 AVANT Immunotherapeutics
- Macro Market Commentary - pgs. 17-18
- Biotech Monthly Coverage Update - pg. 19-22
- NIBM Model Portfolio - pg. 23
- (Full outline below...)
|
 |
|
| This month's Main Story explores vaccine maker
AVANT Immunotherapeutics. The company specializes in making vaccines for bacterial and
viral diseases. The vaccines are typically administered in a single dose by drinking a
small amount of liquid. The company is also pursuing
an anti-cholesterol vaccine aimed at the controversial CETP target. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - AVANT Immunotherapeutics
- Introduction
- Table: Basic Facts
- Disclosures
- Investment thesis
-
- CETi-1
- CETP and Cholesterol
- The race for HDL efficacy
- Reverse lipid transport and HDL science
- Atherosclerosis
- Table: Major particle players
- Reverse Lipid Transport (RLT)
- The CETP controversy
- CETi-1 clinical history
- Phase Ia
- Phase Ib
- Phase II
- Competition
- Pfizer's CP-529,414
- Japan Tobacco's JTT-705
- Competitive picture
- Why care about CETi-1
-
- 89-12/Rotarix
- Rotarix in the clinic
- Follow-up
- Table: Rotarix Phase II results (includes 2-yr follow-up data)
- RotaShield
- Rotarix clinical path
-
- Peru-15/Cholera-Garde
- Clinical experience
-
- Ty-800
-
- Other products
- Traveler's Vaccine line
- Military
- Anthrax
- Complement Inhibitors
- Therapore
- Food safety
-
- Finances and Operations
- Table: AVANT Milestones
What Can Go Wrong
Macro Market Commentary
- Biotech Monthly Coverage Updates
- Nabi
- Dendreon
- PAREXEL
- Esperion
- Table: Timeline updates
- AltaRex
- ID Biomedical
- Alteon
- Onyx Pharmaceuticals
- Alliance Pharmaceuticals
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
